As China's first recognized national high-tech enterprise, Beike Biotechnology’s strong R&D team is led by a dozen stem cell research specialists from all over the world. We are currently focusing on the research and development of adult stem cells, including standardized, large-scale preparation of adult stem cells; clinical translation of adult stem cells for a variety of refractory diseases, such as spinal cord injury, cerebral palsy, Parkinson's disease, premature ovarian failure; research and development of stem cell genetic engineering technology, such as iPS, SOD transgenic and other related technologies. We warmly welcome domestic and international stem cell experts and institutes to contact us for academic exchange and cooperation.
Research & Development
Main Menu
Latest News
- Stem Cell Therapy Shown to be Effective in Treating Liver Cirrhosis
- Beike Earns AABB Accreditation for Cord Blood and Cord Tissue Banking
- ThermoGenesis Announces AABB Accreditation for Beike Biotech
- New Study Finds Cord Blood-derived Stem Cell Treatments Improve Ataxia Patients' Functionality and Quality of Life
- Beike Biotechnology Upgrades Its Processing and Cryopreservation Technology to Expedite Advancements in Stem Cell Therapies
- ThermoGenesis Announces Agreement for AXP and BioArchive Cord Blood Systems With Major Chinese Stem Cell Company
- New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments
- Beike Biotechnology Opens First Chinese Rehabilitation Center in Romania
- Beike Biotech Launches New International Stem Cell Venture
- New Study Demonstrates Improvements in Lupus Patients Receiving Stem Cell Therapies
